Immune checkpoint inhibitors (anti PD‐1 or anti PD‐L1) versus chemotherapy for second‐ or third‐line treatment of metastatic non‐small cell lung cancer

類似資料

• Mesh prophylaxis for hernia in abdominal incisions
  著者:: Penny‐Dimri, Jahan C, 等
  出版事項: (2017)
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
  著者:: Naidoo, J., 等
  出版事項: (2016)
• Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
  著者:: Naidoo, J., 等
  出版事項: (2015)
• Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
  著者:: O’Donnell, Jake S., 等
  出版事項: (2016)
• Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
  著者:: Wei, Spencer C., 等
  出版事項: (2017)